leadf
logo-loader
viewLexaria Bioscience Corp.

Full interview: Lexaria Bioscience and Cannadips CEO’s discuss key point of massive deal together

Lexaria BioScience (OTC: LXRP-CSE: LXX) CEO Chris Bunka and Case Mandel, CEO of Cannadips joined Steve Darling from Proactive Vancouver on Skype with news the company has signed a licensing deal for their DehydraTech technology with Cannadips from Humboldt, California.

Bunka telling Proactive this is a massive deal for the company that will see products in roughly 5000 stores across the U.S. Mandel talks about why they went with Lexaria and how he feels this technology makes them a leader in the space. 
 

Quick facts: Lexaria Bioscience Corp.

Price: 7.69 CAD

CSE:LXX
Market: CSE
Market Cap: $39.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

After successful raise of 11 million dollars, Lexaria Bioscience spells out...

Lexaria Bioscience (NASDAQ: LEXXW- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive with news the company is planning for a very busy 2021 with a number of research and development initiatives. Bunka telling Proactive they are planning research on DehydraTECH-CBD For Hypertension...

3 weeks, 6 days ago

2 min read